STM JOURNALS

Research & Reviews: A Journal of
Biotechnology

https://journals.stmjournals.com/rrjobt/

ISSN: 2231-3826 (Online)
ISSN: 2347-7245 (Print)
Volume 16, Issue 1, 2026
January–April
DOI (Journal): 10.37591/RRJOBT

Review RRJOBT

Innovations in Gene Therapy: Revolutionizing Treatment for Genetic Disorders and Diseases

Disha J. Nagdev[1,*], Beauty A. Yadav[1], Krinal A. Patel[1], Nidhi K. Parmar[1], Bisojeet R. Khandai[1]

Abstract

Gene therapy is a revolutionary intervention in the treatment of genetic diseases since it is an intervention that aims at the very source of diseases, through editing and modification of genes. More recent innovations in gene editing systems, such as CRISPR-Cas9, CRISPR-Cas12, and prime editing, have greatly increased the accuracy and effectiveness of gene therapies, enabling more specific therapies. The opportunities of personalized medicine are also extended by the creation of RNA-based therapies and the use of artificial intelligence (AI) and machine learning, which will allow customizing treatments to the specifics of the genetic makeup. Despite these advances, issues like delivery systems, immune reactions, and regulatory barriers, still remain as barriers to the universal use of gene therapies. Nevertheless, the current clinical trials on diseases, such as Cystic Fibrosis, Duchenne Muscular Dystrophy, and Sickle Cell Anemia, and the possibility to cure such complicated illnesses as cancer and neurodegenerative diseases support the increasing role of gene therapy in contemporary medicine. Gene therapy is the future, which will transform the way diseases are treated around the world.

Keywords: Artificial intelligence, cancer, clinical trials, CRISPR-Cas9, gene editing, gene therapy, genetic disorders, neurodegenerative diseases, personalized medicine, RNA-based therapies

INTRODUCTION TO GENE THERAPY

Gene therapy is defined as the process of specific alteration, replacement, or manipulation of genes in the cells of a patient to prevent or treat diseases with the possibility of a therapeutic result as opposed to the treatment of the symptoms. The idea was developed in the late 20th century, and the initial experimentation on humans started in the 1970s, and the first trials were undertaken in the 1980s. Regardless of the first issues connected with the safety and technical complications, some important achievements were made, among which was the approval of the first commercial gene therapy product in China in 2003. Since it has been found that the technologies of gene delivery, such as the adeno-associated virus (AAV), and gene editing systems, such as CRISPR/Cas9, have transformed the field by enabling the targeting of disease-causing mutations with great specificity [1]. This advance has increased the therapeutic capabilities of gene therapy to treat genetic disorders, blood diseases, and metabolic disorders, and this differs from the traditional curative methods, whereby the main concern is on the symptoms of the illnesses and never the cause of the illness. There are thousands of clinical trials in progress today worldwide, and regulatory bodies have approved several drug therapies based on gene therapy that include hemophilia, spinal muscular atrophy, and hereditary eye diseases. Not only have these developments provided access to the treatment of rare and previously incurable illnesses, but also the development of gene therapies against more common conditions such as cardiovascular diseases and neurodegenerative

***Author for Correspondence**
Disha J. Nagdev
E-mail: dishanagdev.12@gmail.com

[1]Student, Department of Pharmacy Practice, Maliba Pharmacy College, Uka Tarsadia University, Bardoli, Gujarat, India

Received Date: January 27, 2026
Accepted Date: February 12, 2026
Published Date: March 2, 2026

Citation: Disha J. Nagdev, Beauty A. Yadav, Krinal A. Patel, Nidhi K. Parmar, Bisojeet R. Khandai. Innovations in Gene Therapy: Revolutionizing Treatment for Genetic Disorders and Diseases. Research & Reviews: A Journal of Biotechnology. 2026; 16(1): 19–25p.

diseases [2]. The field of gene therapy keeps changing and continues to change due to rising levels of investment, strategic alliances, and growth of commercial innovation. Biotech companies, as well as pharmaceutical giants are investing heavily in gene therapies in the realization of the potential they possess in transforming treatment of various genetic disorders. Nonetheless, there are still issues such as the complicated manufacturing nature, delivery system immunization, high treatment prices, and long-term monitoring of safety [3]. Further, the ethical issues of the germline gene editing, fair access to the treatment, and the future outcomes of the use of genetic manipulation on human evolution are also being discussed. Nevertheless, all these challenges have not diminished the fact that the fast developments in the field of gene therapy are a revelation that can revolutionize the future of the medical profession in terms of ensuring patients with hereditary ailments that cannot be cured can now have a shot and that personalized medicine could be a reality. Since the technology is still in its early stages, it can be anticipated that the genetic therapies will not just cure the genetic diseases but will also transform how we deal with disease prevention and treatment in the decades to come [4].

MECHANISMS AND TECHNIQUES IN GENE THERAPY

Gene therapy entails a variety of sophisticated methods that alter or substitute defective genes. Gene therapy is based on the development of new gene-editing technology, such as using CRISPR-Cas9, Zinc Finger Nucleases (ZFNs), and Transcription Activator-Like Effector Nucleases (TALENs), to redefine or substitute defective genes in cells. Guide RNA CRISPR-Cas9, which directs the Cas9 protein to specific DNA sequences, has been the most utilized technique because of its simplicity, high efficiency, and low cost, making it possible to make specific gene modifications with possible uses in genetic diseases such as cystic fibrosis, sickle cell anemia, and cancer [5]. Although ZFNs and TALENs also make double-strand breaks in DNA using engineered proteins, they are not as popular as CRISPR but are more likely to cause reduced off-target effects, providing high specificity to diseases in which precise corrections are essential such as muscular dystrophy and haemophilia. Another critical aspect is the delivery of genes, in which viral vectors, such as adeno-associated viruses (AAV), lentiviruses, and retroviruses, have proven to be very effective in the transfer of genes, but with some limitations such as immune response and capacity [6]. Alternatively, less risky forms of gene delivery, which are non-viral vectors, are liposomes and nanoparticles. Together with the advances in viral and non-viral vectors, these methods are currently under investigation to cure a variety of genetic disorders, providing the promise of a permanent cure since genetic defects are directly addressed. The benefits, drawbacks, and uses of those methods of gene-editing are summarized in Table 1, emphasizing the idea of the methods in treating various genetic illnesses, some of which are rare and previously incurable [7].

Table 1. Comparison of common gene editing techniques and their applications.

Technique	Mechanism	Strengths	Weaknesses	Common applications
CRISPR-Cas9	Utilizes guide RNA to direct the Cas9 protein to specific DNA sequences for cutting	Simple, efficient, cost-effective	Potential off-target effects, immune response	Cystic fibrosis, sickle cell anemia, cancer.
Zinc Finger Nucleases (ZFNs)	Engineered proteins to recognize and bind to specific DNA sequences, inducing double-strand breaks	High precision, lower off-target effects	Complex design, expensive	Muscular dystrophy, hemophilia.
Transcription Activator-Like Effector Nucleases (TALENs)	Uses transcription activator-like effectors to bind DNA and induce breaks	Highly precise, customizable	Difficult to design, expensive	HIV, cancer, and genetic disorders.

APPLICATIONS OF GENE THERAPY IN GENETIC DISORDERS

Genetic disorder treatment has also become more promising, as the latest technology of gene-editing applies. Cystic Fibrosis and Duchenne Muscular Dystrophy (DMD) are conditions that have been considered as incurable, but there has been a breakthrough that presents hope to the patients. In

Research & Reviews: A Journal of Biotechnology
Volume 16, Issue 1
ISSN: 2231-3826 (Online), 2347-7245 (Print)

the case of Cystic Fibrosis, a faulty CFTR gene leads to the formation of thick mucus, which covers the lungs and the digestive system, and gene therapy will be used to insert an acceptable version of this gene, thus restoring normal functioning. On the same note, in DMD, a mutation in the dystrophin gene causes gradual degeneration of the muscles [8]. Gene therapy can be used to provide the chance of providing the appropriate gene or repair the mutation that is present, thereby ending or reversing the process of muscle wasting. In addition to these commonly known disorders, there are other rare diseases, such as Spinal Muscular Atrophy (SMA), that are also receiving the new technology of gene therapy. In SMA, an abnormally defective SMN1 gene is the cause of weakness in the muscles; however, gene replacement therapy has shown good outcome in which viral vectors are utilized to transfer an active copy of a normal SMN1 gene which can cure the disorder [9]. Although these advancements have been groundbreaking, much more needs to be done on the ethical and safety front. The issue of off-target effects, or unwanted changes to the genome, is still a problem, especially with the application of gene -editing systems like CRISPR-Cas9. Additionally, there is the idea of germline editing, the process of genetic modification of embryos that are transferred to the next generation, which triggers a deeper moral discussion on the consequences of the permanent change in the human genome. Accessibility also comes into play since gene therapies are very expensive, and hence, not everybody may have access to them as required [10]. Figure 1 provides a more in-depth explanation of how technologies, such as CRISPR-Cas9, operate through the step-by-step process of gene editing. The step includes a guide RNA leading the Cas9 protein to a certain spot on the DNA where it leaves a double-strand break. The break is then re-constituted either by insertion of another gene or correction of the mutation, which then puts the normal functioning back. These developments not only demonstrate how enormous the potential of gene therapy is but also bring out the challenges of taking these technologies to clinical practice [11].



Figure 1. Mechanism of CRISPR–Cas9 gene editing.

CHALLENGES IN GENE THERAPY

Gene therapy has demonstrated tremendous potential in alleviating genetic malady, however, there are still major obstacles on the use of gene therapy. Delivery mechanisms are one of the greatest barriers; viral vectors, such as adeno-associated viruses (AAV) and lentiviruses, are the most common vectors as they can effectively deliver genes but have drawbacks as they have limited payload space, they may cause an immune response, and they can cause insertional mutagenesis whereby the inserted gene would alter important genes in the host genome. Non-viral vectors, such as liposomes and nanoparticles, are a safer alternative, as they eliminate most of the risks that viral vectors risk, but they tend to be less effective at gene delivery [12]. The toxicity problems and the immune response is also among the critical challenges with gene therapy because the immune system of the body can perceive viral vectors or modified cells as foreign and thus causing immune attacks. This may lead to inflammation, allergy or other more serious results, like the development of cytokine storms, whereby an excessive response of the immune system may cause widespread tissue damage. Moreover, viral vectors are toxic, so they can be destroyed by the immune system, or, in certain instances, the viral vectors can result in cell damage or even cancerous development because of undesirable genetic integration [13]. One more significant challenge is regulatory hurdles because gene therapies must pass a long period of clinical trials to demonstrate their safety, long-term effectiveness, and possible adverse effects. It is a complicated process since the long-term outcomes of gene therapy have not been fully comprehended, and genetic modifications may have unforeseen outcomes that may be realized after many years. Besides, the expense of gene therapies is still prohibitive as developing and delivering such treatment requires specialized infrastructure and resources, and it is costly to manufacture them [14]. Consequently, the issue of equitable access is of concern especially in low-resource environments, where patients will not be able to access the benefits of such therapies due to the high cost. FDA and the EMA have the challenging responsibility of making sure that gene therapies are safe and effective and making it available to the general population. This is a tradeoff of safety, efficacy, cost, and access that is one of the greatest impediments to successful gene therapy. These types of delivery, immune response, toxicity, and regulatory issues will be key in overcoming gene therapy to achieve its potential as a viable and accessible treatment option to genetic diseases which will ultimately change how medical treatment of previously untreatable diseases will be treated [15].

RECENT BREAKTHROUGHS IN CLINICAL TRIALS

Gene therapy clinical trials have recently made new breakthroughs that have shown great advancements in the treatment of genetic disorders and rare diseases. Among the most remarkable success stories is Zolgensma, a gene therapy of Spinal Muscular Atrophy (SMA) disease, which involved the use of a viral carrier to deliver to patients a functional copy of SMN1 gene. This treatment has demonstrated considerable effectiveness in preventing the development of SMA, which is a life-threatening disorder that causes muscle weakness and atrophy [16]. The other notable development is the application of Luxturna, a gene therapy of Leber congenital amaurosis (LCA) which is a rare genetic disorder that leads to blindness. Luxturna, which provides a normal copy of the RPE65 gene, has now been successful in restoring the vision of patients with the inherited retinal disease. Coupled with these therapies that are approved, other genetic disorders are also undergoing clinical trials that are performing well. Hemophilia B clinical trials, which entail the introduction of the missing clotting factor by means of gene transfer, have shown a lasting therapeutic effect, which has lessened the frequency of clotting factor injections in patients and boosted their quality of life [17]. On the same note, gene therapy in sickle cell anemia is bearing fruit with clinical trials being done to correct the genetic mutation causing the disease using CRISPR-Cas9. These advancements are a new dawn in the management of genetic illnesses, and more is being done to enhance the efficiency, safety, and accessibility of gene therapies. These and other current studies are summarized in Table 2 and demonstrate that the field of gene therapy has a growing potential in the treatment of common and rare genetic diseases [18].

FUTURE DIRECTIONS IN GENE THERAPY

The future of gene therapy is poised to transform the medical field with the next generation gene editing instruments as well as possibilities of its large-scale usage in a variety of medical disciplines.

Although the current technologies, such as CRISPR-Cas9 and ZFNs, have shown promise, continuous process, is aimed at advancing the accuracy, efficiency, and safety of the modifications in genes [19]. More recent technologies, like the CRISPR-Cas12 and CRISPR-Cas13, which enable more specific edits not only in DNA but also in RNA, are broadening the range of gene therapy to target diseases that are based on RNA. In addition, novel technologies, such as base editing and prime editing, can make a highly specific modification in the genome without causing double-strand breaks, minimizing the risk of undesired genetic mutations. Such developments will enable gene therapy to play a major role in personalized medicine where its treatment is based on the genetic profile of an individual and provide more effective and specific therapy to a variety of diseases [20]. Incorporation of artificial intelligence (AI) and machine learning (ML) into gene editing technologies will further fasten the creation of such individualized therapy, improving the design and discovery of novel therapies. The potential of gene therapy has been expanded to encompass other complex diseases like cancer, heart disease and neurodegenerative diseases in addition to hereditary diseases. Figure 2 presents these new trends in gene therapy and personalized medicine with the focus on the changes in technologies and the transformative effect on healthcare. As technology advances, gene therapy will be more effective, affordable, and accessible and eventually enhance patients, as well as increase its use in a wide range of diseases [21].

Table 2. Summarizes recent breakthroughs in clinical trials.

Breakthrough	Disease targeted	Gene therapy approach	Key outcomes	Status
Zolgensma	Spinal Muscular Atrophy (SMA)	Viral vector delivery of the SMN1 gene	Significant improvement in motor function, halting disease progression.	Approved.
Luxturna	Leber Congenital Amaurosis (LCA)	Delivery of the RPE65 gene to retinal cells	Restored vision in patients with this inherited retinal disorder.	Approved.
Hemophilia B Gene Therapy	Hemophilia B	Gene transfer of the Factor IX gene	Long-term therapeutic effects, reduced need for clotting factor infusions.	Ongoing Trials.
Sickle Cell Anemia (CRISPR)	Sickle Cell Anemia	CRISPR-Cas9 to correct the HBB gene mutation	Improved hemoglobin production, reduced symptoms of sickle cell disease.	Ongoing Trials.



Figure 2. Emerging trends and future directions in gene therapy.

CONCLUSION

To sum up, gene therapy is on the brink of medical innovation, and it is with this that it has provided unparalleled opportunities to treat and possibly cure genetic disorders due to its ability to provide solutions to the cause of diseases. The quality and efficiency of gene therapies have been increasingly refined over the years with the development of new gene editing technologies, such as CRISPR-Cas9, CRISPR-Cas12 and prime editing, making them more accessible to a wide variety of conditions. The development of RNA-based therapies along with the use of AI and machine learning is increasing the therapeutic options, which will allow treating individuals with greater specificity, according to their genetic profile. Although these issues still exist, such as the delivery mechanisms, immune reactions, and regulatory barriers, the achievements that have been achieved so far demonstrate the potential transformation that gene therapy can bring. The future of gene therapy is bright as clinical trials continue to show success in treating not only genetic disorders but also highly complex diseases such as cancer, neurodegenerative conditions and others. As research continues, further advancement in innovation and better regulatory systems, the application of gene therapy can change how we look at treating diseases and make the future where personalized and precision medicine is commonly available to patients everywhere in the world a reality.

REFERENCES

1. Ay C, Reinisch A. Gene therapy: principles, challenges and use in clinical practice. Wiener Klinische Wochenschrift. 2025 May;137(9):261-71.
2. Kaur G, Arora J, Sodhi AS, Bhatia S, Batra N. Nanotechnology and CRISPR/Cas-mediated gene therapy strategies: Potential role for treating genetic disorders. Mol Biotechnol. 2025;67(10):3800–3822.
3. Jakabek D, Isaacs AM, De Strooper B, Tuszynski M, Lane R, Uspenskaya O, McDade E, Rafii MS, Mummery CJ. CTAD taskforce: genetic therapies in Alzheimer’s disease. The Journal of Prevention of Alzheimer's Disease. 2025 Jul 9:100269.
4. Bamarinejad F, Shokoohi M, Bamarinejad A. Gene therapy for obsessive–compulsive disorder: Basic research and clinical prospects. Pers Med Psychiatry. 2025;49:100149.
5. Wailoo K, Pemberton S. The troubled dream of genetic medicine: ethnicity and innovation in Tay-Sachs, cystic fibrosis, and sickle cell disease. JHU Press; 2006 May 29.
6. Parisi GF, Terlizzi V, Manti S, Papale M, Pecora G, Presti S, Tosto M, Leonardi S. Cutting-edge advances in cystic fibrosis: from gene therapy to personalized medicine and holistic management. Genes. 2025 Mar 30;16(4):402.
7. Superson M, Szmyt K, Wilk-Trytko K, Krasnoborska J, Samojedny S, Szymańska K, Walczak K. Applications of gene modification technologies in the treatment of inherited diseases. Journal of Education, Health and Sport. 2024 Apr 18;66:50073-.
8. Silverberg S. Can cystic fibrosis be treated with genetic therapy? Sci J Lander Coll Arts Sci. 2025;18(2):106–114.
9. Patel A. Advances in Therapeutic Strategies for the Genetic Disorder Cystic Fibrosis. THE AMERICAN JOURNAL OF STUDENT RESEARCH Учредители: HY Academy. 2025.
10. Ferrari S, Geddes DM, Alton EW. Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis. Adv Drug Deliv Rev. 2002;54(11):1373–1393.
11. Lomunova M, Gershovich PM. Gene therapy for cystic fibrosis: recent advances and future prospects. Acta Naturae. 2023;15(2):20–31.
12. Baum C, Kustikova O, Modlich U, Li Z, Fehse B. Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther. 2006;17(3):253–263.
13. Koonin EV, Krupovic M. Evolution of adaptive immunity from transposable elements combined with innate immune systems. Nat Rev Genet. 2015;16(3):184–192.
14. Ranzani M, Annunziato S, Adams DJ, Montini E. Cancer gene discovery: Exploiting insertional mutagenesis. Mol Cancer Res. 2013;11(10):1141–1158.
15. Bushman FD. Retroviral insertional mutagenesis in humans: Evidence for four genetic mechanisms promoting expansion of cell clones. Mol Ther. 2020;28(2):352–356.

16. Ponomarev AS, Chulpanova DS, Yanygina LM, Solovyeva VV, Rizvanov AA. Emerging gene therapy approaches in the management of spinal muscular atrophy (SMA): An overview of clinical trials and patent landscape. Int J Mol Sci. 2023;24(18):13743.
17. Li Y, Zeng H, Wei Y, Ma X, He Z. An overview of the therapeutic strategies for the treatment of spinal muscular atrophy. Hum Gene Ther. 2023;34(5–6):180–191.
18. de Figueiredo AC. Real-world effectiveness of gene therapy Zolgensma®(Onasemnogene Abeparvovec-xioi) for the treatment of Spinal Muscular Atrophy (SMA) (Master's thesis, Universidade de Lisboa (Portugal)).
19. Arjmand B, Larijani B, Sheikh Hosseini M, Payab M, Gilany K, Goodarzi P, Parhizkar Roudsari P, Amanollahi Baharvand M, Hoseini Mohammadi NS. The horizon of gene therapy in modern medicine: advances and challenges. Cell Biology and Translational Medicine, Volume 8: Stem Cells in Regenerative Medicine. 2019 Dec 17:33-64.
20. Niazi SK. The dawn of in vivo gene editing era: A revolution in the making. Biologics. 2023;3(4):253–295.
21. Roy R, Shahanaz A, Marakkar S, Natarajan P, P Anil A, Kunnathpeedikayil S, Vadakkan Cherian A, Ganguly P, Munnangi P, Yadav V, Pandita S. Cell and Gene Therapy: Current Landscape, Emerging Trends and Future Prospects.

